
Septerna Inc (SEPN) Stock Forecast & Price Target
Septerna Inc (SEPN) Analyst Ratings
Bulls say
Septerna Inc., a clinical-stage biotechnology firm, has an enterprise value of approximately $430 million, representing a significant potential for long-term upside of 8-10 times its current share price, particularly should its collaboration with Novo prove successful. The company's diverse pipeline, including promising candidates like SEP-631, has the potential to replicate the success of existing blockbuster therapies, such as Xolair, thereby unlocking considerable market opportunities. Additionally, Septerna's proprietary Native Complex Platform and strategic partnerships, especially in the lucrative obesity market, position the company for substantial future growth and value creation.
Bears say
Septerna Inc. faces multiple risks that contribute to a negative outlook on its stock, including potential delays and setbacks in clinical development and trials for its product candidates. There are also significant concerns regarding the stability of partnerships, particularly with Novo Nordisk, and the possibility of failing to secure necessary approvals for key therapies. Furthermore, lower-than-expected market penetration rates and the risk of long-term dilution present additional financial uncertainties that could adversely affect the company's valuation.
This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.
Septerna Inc (SEPN) Analyst Forecast & Price Prediction
Start investing in Septerna Inc (SEPN)
Order type
Buy in
Order amount
Est. shares
0 shares